Fierce Biotech

Gilead’s $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos

Published

2 weeks ago

on

Gilead is paying $1.68 billion for a T-cell engager company via a front-loaded deal that could also give new meaning to its aimless partner Galapagos.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version